PT - JOURNAL ARTICLE AU - Behnam Keshavarz AU - Joesph R. Wiencek AU - Lisa J. Workman AU - Matthew D. Straesser AU - Lyndsey M. Muehling AU - Glenda Canderan AU - Fabrizio Drago AU - Catherine A. Bonham AU - Jeffrey M. Sturek AU - Chintan Ramani AU - Coleen A. McNamara AU - Judith A. Woodfolk AU - Alexandra Kadl AU - Thomas A.E. Platts-Mills AU - Jeffrey M. Wilson TI - Quantitative measurement of IgG to SARS-CoV-2 proteins using ImmunoCAP AID - 10.1101/2020.11.09.20228411 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.09.20228411 4099 - http://medrxiv.org/content/early/2020/11/12/2020.11.09.20228411.short 4100 - http://medrxiv.org/content/early/2020/11/12/2020.11.09.20228411.full AB - Background Detailed understanding of the immune response to SARS-CoV-2, the cause of coronavirus disease 2019 (COVID-19), has been hampered by a lack of quantitative antibody assays.Objective To develop a quantitative assay for IgG to SARS-CoV-2 proteins that could readily be implemented in clinical and research laboratories.Methods The biotin-streptavidin technique was used to conjugate SARS-CoV-2 spike receptor-binding-domain (RBD) or nucleocapsid protein to the solid-phase of the ImmunoCAP resin. Plasma and serum samples from patients with COVID-19 (n=51) and samples from donors banked prior to the emergence of COVID-19 (n=109) were used in the assay. SARS-CoV-2 IgG levels were followed longitudinally in a subset of samples and were related to total IgG and IgG to reference antigens using an ImmunoCAP 250 platform.Results Performance characteristics demonstrated 100% sensitivity and 99% specificity at a cut-off level of 2.5 µg/mL for both SARS-CoV-2 proteins. Among 36 patients evaluated in a post-hospital follow-up clinic, median levels of IgG to spike-RBD and nucleocapsid were 34.7 µg/mL (IQR 18-52) and 24.5 µg/mL (IQR 9-59), respectively. Among 17 patients with longitudinal samples there was a wide variation in the magnitude of IgG responses, but generally the response to spike-RBD and to nucleocapsid occurred in parallel, with peak levels approaching 100 µg/mL, or 1% of total IgG.Conclusions We have described a quantitative assay to measure IgG to SARS-CoV-2 that could be used in clinical and research laboratories and implemented at scale. The assay can easily be adapted to measure IgG to novel antigens, has good performance characteristics and a read-out in standardized units.Competing Interest StatementTPM has a patent on an IgE assay to α-Gal and has received assay support from Thermo Fisher Scientific. JW has received consultant fees and assay support from Thermo Fisher Scientific. The other authors have no conflicts of interest to declare.Funding StatementNIH T32 AI007496 (LM), NIH K23HL143135 (CB), UL1TR003015 and KL2TR003016 (JS), NIH R37 AI20565 (TPM), UVA Manning COVID-19 Research Fund and AAAAI Faculty Development Award (JW).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board for Health Sciences Research at the University of Virginia.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPrimary data is available on request from the corresponding author.